Medtronic has completed its purchase of CathWorks, integrating the FFRangio System into its cardiovascular portfolio. The deal aims to enhance the company's AI-driven heart diagnostic capabilities.
- Acquisition value of $585 million plus potential earn-outs
- Integration of FFRangio System into cardiovascular portfolio
- Follows a 2022 co-promotion agreement
- Immaterial impact on FY2027 GAAP and adjusted EPS
- Expected to be neutral to accretive in future periods
Sign up free to read the full analysis
Create a free account to unlock full AI-curated market articles, personalized alerts, and more.